Compare LION & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LION | GRDN |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | Canada | United States |
| Employees | N/A | 3400 |
| Industry | Movies/Entertainment | Retail-Drug Stores and Proprietary Stores |
| Sector | Consumer Discretionary | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | 2025 | N/A |
| Metric | LION | GRDN |
|---|---|---|
| Price | $10.32 | $32.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | $10.06 | ★ $33.33 |
| AVG Volume (30 Days) | ★ 2.5M | 141.9K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,195,500,000.00 | N/A |
| Revenue This Year | N/A | $19.50 |
| Revenue Next Year | $22.98 | N/A |
| P/E Ratio | ★ N/A | $117.77 |
| Revenue Growth | ★ 7.00 | N/A |
| 52 Week Low | $5.65 | $18.37 |
| 52 Week High | $11.02 | $37.43 |
| Indicator | LION | GRDN |
|---|---|---|
| Relative Strength Index (RSI) | 64.84 | 46.66 |
| Support Level | $5.92 | $31.82 |
| Resistance Level | N/A | $34.98 |
| Average True Range (ATR) | 0.47 | 1.28 |
| MACD | 0.22 | -0.25 |
| Stochastic Oscillator | 75.17 | 23.23 |
Lionsgate Studios Corp is a motion picture and television studio operations aligned with the STARZ premium subscription platform to bring a varied portfolio of entertainment to consumers around the world. The group has two reportable business segments: the Motion Picture and Television Production reportable segments. Motion Picture consists of the development and production of feature films, the acquisition of North American and world-wide distribution rights. Television Production consists of the development, production, and world-wide distribution of television productions, including television series, television movies and mini-series, and non-fiction programming.
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.